Literature DB >> 23289944

Screening for substance abuse and diversion in Virginia hospices.

Leslie J Blackhall1, Elizabeth D Alfson, Joshua S Barclay.   

Abstract

BACKGROUND: Although inadequate treatment of pain is a problem for hospice patients, increases in the medical use of opioids have been accompanied by increasing levels of abuse and diversion in the community. Balancing pain relief with concerns about abuse and diversion is a difficult issue for hospices.
OBJECTIVES: The aim of this study was to determine policies and practices in Virginia hospices regarding substance abuse and diversion in patients and their families.
METHODS: A survey was conducted of Virginia hospices about policies, perceptions, and training regarding substance abuse and diversion.
RESULTS: Twenty-three of 63 hospice agencies responded (36.5%). Less than half (43.8%) required mandatory substance abuse training. Only 43.5% had policies regarding screening for substance abuse in patients; 30.4% had a policy regarding screening for substance abuse in family members. Policies regarding screening for diversion in patients (21.7%), and families (17.4%) were rare. Policies regarding opioid use in patients with a history of substance abuse or diversion were uncommon (33.3%, 30.4%, respectively); 30.4% had policies regarding use of opioids in patients whose family members had a history of diversion or abuse. Thirty-eight percent of hospices agreed that substance abuse and diversion was a problem for their agency, and these agencies were more likely to have written policies or mandatory training.
CONCLUSION: Most Virginia hospices lack mandatory training and policies regarding substance abuse and diversion in patients and family members. More than one-third felt that abuse and diversion were problems in their agencies. A national conversation regarding policies toward substance abuse and diversion in hospice agencies is needed.

Entities:  

Mesh:

Year:  2013        PMID: 23289944     DOI: 10.1089/jpm.2012.0263

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  8 in total

Review 1.  Lifestyle Medicine Interventions in Patients With Advanced Disease Receiving Palliative or Hospice Care.

Authors:  Gowri Anandarajah; Haran Asher Mennillo; Gregory Rachu; Tyler Harder; Jyotsna Ghosh
Journal:  Am J Lifestyle Med       Date:  2019-02-15

Review 2.  Best Practices in the Management of Nonmedical Opioid Use in Patients with Cancer-Related Pain.

Authors:  Esad Ulker; Egidio Del Fabbro
Journal:  Oncologist       Date:  2019-12-24

3.  Patterns of storage, use, and disposal of opioids among cancer outpatients.

Authors:  Akhila Reddy; Maxine de la Cruz; Eden Mae Rodriguez; Jessica Thames; Jimin Wu; Gary Chisholm; Diane Liu; Susan Frisbee-Hume; Sriram Yennurajalingam; David Hui; Hilda Cantu; Alejandra Marin; Vicki Gayle; Nancy Shinn; Angela Xu; Janet Williams; Eduardo Bruera
Journal:  Oncologist       Date:  2014-05-27

Review 4.  Safe Opioid Use, Storage, and Disposal Strategies in Cancer Pain Management.

Authors:  Akhila Reddy; Maxine de la Cruz
Journal:  Oncologist       Date:  2019-05-16

Review 5.  An overview of abuse-deterrent opioids and recommendations for practical patient care.

Authors:  Jeremy A Adler; Theresa Mallick-Searle
Journal:  J Multidiscip Healthc       Date:  2018-07-11

6.  How I treat pain in hematologic malignancies safely with opioid therapy.

Authors:  Holly L Geyer; Halena Gazelka; Ruben Mesa
Journal:  Blood       Date:  2020-06-25       Impact factor: 22.113

7.  Managing Opioids and Mitigating Risk: A Survey of Attitudes, Confidence and Practices of Oncology Health Care Professionals.

Authors:  Alissa Tedesco; Jocelyn Brown; Breffni Hannon; Lauren Hutton; Jenny Lau
Journal:  Curr Oncol       Date:  2021-02-12       Impact factor: 3.677

Review 8.  Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review.

Authors:  Ashley-Nicole Carmichael; Laura Morgan; Egidio Del Fabbro
Journal:  Subst Abuse Rehabil       Date:  2016-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.